. Author manuscript; available in PMC: 2016 Jun 30.

Published in final edited form as: Mayo Clin Proc. 2015 Jul 9;90(8):1030–1037. doi: 10.1016/j.mayocp.2015.05.011

TABLE 2.

Annualized Rates of Change in Total Liver Volume by Study Period (Censored for Patients Who Had Liver Cyst Aspiration)^a

Original 12-mo trial Treatment	Patients, No.	Annualized rate (%/y), mean ± SD
Original 12-mo trial Treatment	Patients, No.	Baseline to year 1	Year 1 to year 2 (on drug)	Year 2 to OLE_baseline (off drug)	OLE_baseline to OLE_end (on drug)
Octreotide	13	−6.5±4.9 (on drug)	−3.9±5.9	4.0±10.2	−5.7±6.7
Placebo	8	−1.7±8.9 (off drug)	−8.3±12.3	2.4±4.7	−3.2±5.1
Total	21	NA	−5.6±9.0^b	3.4±8.2	−4.7±6.1^c
P value (total rate=0)		NA	.01	.11	.002

NA = not available; OLE_baseline = reenrollment in a 2-year open-label extension study; OLE_end = open-label extension study completion.

P<.001 for total group rate of change on drug from year 1 to year 2 (−5.6%) vs year 2 to OLE_baseline, off drug (3.4%).

P=.001 for total group rate of change on drug from OLE_baseline to OLE_end (−4.7%) vs year 2 to OLE_baseline, off drug (3.4%).